

Comparison between alendronate oral jelly and alendronate weekly tablet in the treatment of osteoporosis in Japan

Nobukazu Okimoto, MD, Ph.D ¹⁾; Satoshi Ikeda, MD, Ph.D ²⁾; Hidehiro Matsumoto, MD ³⁾; Akinori Sakai, MD, Ph.D ⁴⁾

1) Okimoto clinic 2) Ken-Ai Memorial hospital 3) Sanzai hospital
4) University of Occupational and Environmental Health, Japan

Background & Purpose

Alendronate oral jelly (ALN-J, 35mg, once weekly) as a new formulation was launched in 2013, however, little is known about the efficacy and safety of ALN-J in the treatment of osteoporosis. We conducted the comparative trial of alendronate oral jelly (ALN-J, 35mg) versus alendronate weekly tablet (ALN-T, 35mg) to clarify the effect of alendronate oral jelly in the treatment of osteoporosis in Japanese clinical settings.

Methods

- We allocated ALN-J or ALN-T to the patients in accordance with their preferences in each institution.
- The patients took ALN-J or ALN-T weekly and were observed for 6 months.
- Bone turnover marker (TRACP-5b, P1NP) was measured at baseline, 3 months and 6 months and bone mineral density was measured at baseline and 6 months.




Results

Baseline characteristics



	ALN-J	ALN-T
Gender	F: 62, M: 3	F: 27, M: 2
Age, years	77.5 (7.6)	76.0 (6.6)
Height, cm	148.8 (6.9)	150.6 (6.8)
Weight, kg	49.8 (8.7)	51.3 (8.7)
TRACP-5b, mU/dL	488.4 (186.1)	526.8 (184.3)
P1NP, µg/L	62.9 (35.4)	58.4 (20.2)
L-BMD, % YAM	74.7	74.4
FN-BMD, % YAM	62.1	63.7
Hip-BMD, % YAM	68.4	71.8
Radius-BMD, % YAM	68.4	70.6
History of Fx, %	74	83

(): SD

Bone mineral density



Bone turnover marker



Conclusions

- ALN-J has equal effectiveness to ALN-T.
- ALN-J is considered to be an option in the treatment of osteoporosis in Japan.

Disclosure

The authors have no conflict of interest directly relevant to this study.